{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:40:05Z","timestamp":1756374005314,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,7]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>This case report describes a woman in her 50s with a rare coexistence of neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), highlighting the diagnostic challenges and therapeutic considerations. Initially diagnosed with acetylcholine receptor antibody-positive MG, she later developed progressive visual impairment, leading to a diagnosis of NMOSD. Rituximab treatment was effective in managing both conditions, demonstrating the benefits of targeted therapies in reducing complications related to polypharmacy. This case underscores the importance of clinical vigilance and a multidisciplinary approach in managing overlapping autoimmune disorders, offering insights into their inter-relationships and therapeutic strategies.<\/jats:p>","DOI":"10.1136\/bcr-2024-263081","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T22:50:28Z","timestamp":1736031028000},"page":"e263081","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent myasthenia gravis and neuromyelitis optica spectrum disorder: a rare intersection of autoimmune pathologies"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-5285","authenticated-orcid":false,"given":"Abdulkadir","family":"Tun\u00e7","sequence":"first","affiliation":[{"name":"Department of Neurology, Sakarya University Faculty of Medicine, Sakarya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer","family":"El\u00e7\u0130","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sakarya University Faculty of Medicine, Sakarya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alihan","family":"Akbas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sakarya University Faculty of Medicine, Sakarya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samet","family":"Oncel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ministry of Health Sakarya Education and Research Hospital, Adapazari, Sakarya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"2025082802074439000_18.1.e263081.1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.msard.2018.01.007","article-title":"Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis","volume":"20","author":"Fan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2025082802074439000_18.1.e263081.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.44"},{"key":"2025082802074439000_18.1.e263081.3","doi-asserted-by":"crossref","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"2025082802074439000_18.1.e263081.4","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025082802074439000_18.1.e263081.5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.790941","article-title":"Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort","volume":"12","author":"Shi","year":"2021","journal-title":"Front Neurol"},{"key":"2025082802074439000_18.1.e263081.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2025082802074439000_18.1.e263081.7","doi-asserted-by":"crossref","first-page":"102205","DOI":"10.1016\/j.msard.2020.102205","article-title":"Anti-MOG and Anti-AQP4 positive neuromyelitis optica spectrum disorder in a patient with myasthenia gravis","volume":"44","author":"Bates","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025082802074439000_18.1.e263081.8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12599"},{"key":"2025082802074439000_18.1.e263081.9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"},{"key":"2025082802074439000_18.1.e263081.10","first-page":"1601","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurol (ECronicon)"},{"key":"2025082802074439000_18.1.e263081.11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"2025082802074439000_18.1.e263081.12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology (ECronicon)"},{"key":"2025082802074439000_18.1.e263081.13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00415-019-09498-4","article-title":"Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review","volume":"268","author":"Chamberlain","year":"2021","journal-title":"J Neurol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:07:56Z","timestamp":1756372076000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,4]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bcr-2024-263081"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263081","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}